OC
ADAP

Oppenheimer & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

Oppenheimer & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,043
Closed -$17.3K – 1568
2024
Q4 		$17.3K Sell
32,043
-4,232
-12% -$3.08K ﹤0.01% 1542
2024
Q3 		$34.5K Sell
36,275
-3,023
-8% -$3.43K ﹤0.01% 1490
2024
Q2 		$38.3K Sell
39,298
-4,534
-10% -$4.98K ﹤0.01% 1411
2024
Q1 		$69.3K Sell
43,832
-6,271
-13% -$7.57K ﹤0.01% 1402
2023
Q4 		$39.7K Sell
50,103
-18,068
-27% -$10.2K ﹤0.01% 1357
2023
Q3 		$53.2K Hold
68,171
– – ﹤0.01% 1340
2023
Q2 		$63.1K Buy
+68,171
New +$81.3K ﹤0.01% 1372
2020
Q4 		– Sell
-36,837
Closed -$294K – 1341
2020
Q3 		$294K Buy
+36,837
New +$322K 0.01% 989

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co's ADAP Position: Q1 2025 in Review

Oppenheimer & Co sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 32,043 shares — an estimated $17.3K sold.

Oppenheimer & Co first reported a position in ADAP in Q3 2020 and held it in 8 quarters. The position peaked at $294K in Q3 2020. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Oppenheimer & Co reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 32,043 Adaptimmune Therapeutics shares in Q1 2025, an estimated $17.3K.
  • Oppenheimer & Co first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 8 quarters.
  • Oppenheimer & Co's Adaptimmune Therapeutics position peaked at $294K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.